Lundbeck Snaps Up Parkinson's Developer Prexton In Deal Worth €905m
Executive Summary
Lundbeck has swooped in to buy Merck KGaA spinout Prexton Therapeutics for €100m upfront, prior to Phase II data readouts for its potential first-in-class Parkinson's drug, foliglurax.
You may also be interested in...
Deal Watch: Opportunity Knocks For Partnerships In Asia
ApolloBio signs on to take Inovio's HPV immunotherapy into China and Senju and Fosun sign China partnerships – all part of a wave of Chinese companies looking to bring innovative new medicines to the Greater China markets. Meanwhile, GSK signs on with Indian CRO Syngene.
Merck Spin-Off Prexton Turns mGluR4 Fortunes Around In Parkinson's Disease
Prexton Therapeutics has the only mGluR4-targeting drug candidate in clinical testing, after a number of big pharma dropped preclinical programs. The company has just secured €29m to fund two Phase II trials.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.